Head/Neck Cancers Symposium 2020: Immunotherapy Plus TKIs in Metastatic Thyroid Cancer
Posted: Friday, March 20, 2020
Joining tyrosine kinase inhibitors (TKIs) and immunotherapy appears to be an efficient combined therapy for metastatic thyroid cancer, according to Ashleigh Porter, MD, of the David Geffen School of Medicine at the University of California Los Angeles, and colleagues. The investigators believe that further studies are warranted to understand the synergistic effects of the combination. These results were presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona (Abstract 346).
The single-institution retrospective case series included six patients with metastatic thyroid cancer. The median age was 62.5 years; four were female and two were male. One patient had metastatic disease at diagnosis, and the median number of prior systemic therapies was 3.5. The median number of prior TKIs was two; for prior immunotherapies, the median number was one. The patients were subsequently treated with TKIs in conjunction with an immunotherapeutic agent.
Five of the patients experienced drug-related adverse events due to tyrosine kinase inhibition. The significant adverse events reported included diarrhea (66%), hypertension (33%), and transaminitis (33%). Although one of the patients continued to respond well to therapy, treatment was discontinued because transaminitis led to drug-induced liver injury. The median time on the combination therapy was 255 days. Although three of the patients died, the other three were still on therapy at the time of the analysis.
Disclosure: For full disclosures of the study authors, visit headandnecksymposium.org.